Please use this identifier to cite or link to this item:
|Title:||Phadiatop as a screening method for prescribing immunobiological therapy|
|Citation:||Naumova, Veronika. Phadiatop as a screening method for prescribing immunobiological therapy / Veronika Naumova, Evgeny Beltyukov, Tatyana Lepeshkova [and ot.] // EMJ Allergy Immunol: Abstract Review No. AR1. - 2021. – №6. -C.33-35.|
|Abstract:||Over the past two decades, new opportunities have emerged in the treatment of severe bronchial asthma due to the development of immunobiological therapy. The effectiveness of biologics depends on correct phenotyping of asthma in patients.1 The Phadiatop test has been known since the 1980s and has established itself as a screening test for the detection of atopy, allergic rhinitis, and allergic asthma.2-9 When selecting patients with severe bronchial asthma for targeted therapy in the Sverdlovsk region, Russia, the Phadiatop™ (Phadia AB, Uppsala, Sweden) screening test was used for phenotyping asthma in this group of patients|
SEVERE BRONCHIAL ASTHMA
|Origin:||ALLERGY & IMMUNOLOGY|
|Appears in Collections:||Публикации в журналах, альманахах|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.